Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in Inflammatory Bowel Disease Patients Treated With Vedolizumab
Phase of Trial: Phase IV
Latest Information Update: 20 Jul 2018
At a glance
- Drugs Vedolizumab (Primary) ; Hepatitis B vaccine; Influenza virus vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
- Indications Inflammatory bowel diseases
- Focus Pharmacodynamics
- 12 Jul 2018 Planned End Date changed from 30 Jun 2018 to 31 Dec 2019.
- 12 Jul 2018 Planned primary completion date changed from 30 Jun 2018 to 31 Dec 2019.
- 10 Jul 2017 Status changed from not yet recruiting to recruiting.